Esmeron Injection
Rocuronium Bromide
10mg/ml
N.V. ORGANON
| Pack size | 5ml Vial x 10 |
|---|---|
| Dispensing mode | POM |
| Source | NETHERLANDS |
| Agent | CITY MEDICAL STORE |
| Retail Price | 298.00 AED |
Available as:
Indications
Esmeron Injection is used for:
Endotracheal intubation, Aid controlled ventilation, Muscle relaxant in general anesthesia
Adult Dose
Intravenous
Muscle relaxant in general anaesthesia; Facilitate endotracheal intubation; Facilitate mechanical ventilation in intensive care
Adult: Initially, 600 mcg/kg by inj. Higher doses of 1 mg/kg may be used for intubation during rapid sequence induction of anaesth. Maintenance: 150 mcg/kg by inj (may reduce to 75-100 mcg/kg for prolonged inhalational anaesth) or by infusion at 300-600 mcg/kg/hr.
Elderly: Maintenance: 75-100 mcg/kg.
Hepatic impairment: Maintenance: 75-100 mcg/kg by inj or 300-400 mcg/kg/hr by infusion.
Child Dose
Intravenous
Muscle relaxant in general anaesthesia; Facilitate endotracheal intubation; Facilitate mechanical ventilation in intensive care
Child: Initially, 600 mcg/kg by inj. Higher doses of 1 mg/kg may be used for intubation during rapid sequence induction of anaesth. Maintenance: 150 mcg/kg by inj (may reduce to 75-100 mcg/kg for prolonged inhalational anaesth) or by infusion at 300-600 mcg/kg/hr.
Renal Dose
Renal impairment: Maintenance: 75-100 mcg/kg by inj or 300-400 mcg/kg/hr by infusion.
Administration
IV Preparation
Dilute with D5W or LR to a final concentration of 0.5 or 1 mg/mL for infusion
IV Administration
Administer IV only
May be given undiluted as a rapid injection or via continuous infusion using an infusion pump
Contra Indications
Hypersensitivity.
Precautions
Patient w/ biliary tract disease, neuromuscular disease, previous poliomyelitis, burn injury, severe electrolyte disturbances, Eaton-Lambert syndrome, myasthenia gravis, CV disease, resp disease, pulmonary HTN; obese patients. Renal and hepatic impairment. Elderly. Pregnancy and lactation. Monitoring Parameters Monitor heart rate, BP, twitch response, assisted ventilation status.
Lactation: not known if excreted in breast milk; effect on nursing infant not known
Pregnancy-Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk; effect on nursing infant not known
Interactions
May cause enhanced block when used with lidocaine, procainamide, quinidine, verapamil, aminoglycosides, inhalational anaesthetics and vancomycin. May cause prolonged paralysis when used with clindamycin. Anticholinesterases such as pyridostigmine and galantamine may antagonise the effect of rocuronium. Chronic use of carbamazepine or phenytoin may lead to resistance to rocuronium.
Adverse Effects
Side effects of Rocuronium Bromide :
1-10%
Transient hypotension (1-2%), Hypertension (1-2%)
<1%
Dose-related tachycardia, Apnea, Abnormal ECG, Injection site edema, Hiccups, Pruritus, Nausea, Wheezing, Residual muscle weakness, Allergic or idiosyncratic hypersensitivity reactions
Potentially Fatal: Abnormal ECG, arrhythmia, bronchospasm, anaphylaxis and malignant hyperthermia.
Mechanism of Action
Rocuronium is a competitive neuromuscular blocker that acts by blocking the binding of acetylcholine to receptors on the motor endplate, inhibiting depolarisation.
Note
Esmeron 10mg/ml Injection manufactured by N.V. ORGANON. Its generic name is Rocuronium Bromide. Esmeron is availble in United Arab Emirates.
Farmaco UAE drug index information on Esmeron Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.